Hi meab. I am familiar with the announcement around recruitment,...

Hi meab.

I am familiar with the announcement around recruitment, and the stabilisation period before dosing. Hence the surprise when hearing on the interview that the 72nd patient has not yet been dosed. Even if that patient had failed during the process, there were others continually recruited - so some undisclosed hiccups to be at the end of April and still not finished.

Given the link suppression, for those that are interested it is on stock*head and look for DXB. Dated 20th April @ 22minutes15seconds for the final minute discussing the 72nd patient as for near term newsflow.

DXB are still recruiting for a P3 trial (currently at 94). When questioned about money, there was talk about an R&D advance, partnership deal and avoided mentioning a CR. Those are the 3 options, of which the latter 2 are the most viable, depending how far partnership talk has progressed.